Company Description
Canton Strategic Holdings, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets.
The company also involved in research and development of GV104, a buccal film technology, which has completed Phase 1 trial for respiratory and/or nervous system depression in military personnel and chemical incident responders; and GV023, an oral formulation of infliximab, addresses a critical limitation of the IV gold standard by eliminating the treatment burden of repeated intravenous infusions.
The company was formerly known as Tharimmune, Inc. and changed its name to Canton Strategic Holdings, Inc. in February 2026.
Canton Strategic Holdings, Inc. was founded in 2017 and is based in Red Bank, New Jersey.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jan 12, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Mark Wendland |
Contact Details
Address: 34 Shrewsbury Avenue, Suite 1C Red Bank, New Jersey 07701 United States | |
| Phone | 732 889 3111 |
| Website | tharimmune.com |
Stock Details
| Ticker Symbol | CNTN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1861657 |
| CUSIP Number | 432705309 |
| ISIN Number | US4327053090 |
| Employer ID | 84-2642541 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mark Wendland | Chief Executive Officer and Chairman of the Board |
| Mark Toomey | President |
| Jacob Asbury | Chief Financial Officer |
| Angela Radkowski | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 3, 2026 | 8-K | Current Report |
| Mar 3, 2026 | 424B5 | Filing |
| Mar 3, 2026 | 8-K | Current Report |
| Feb 18, 2026 | 8-K | Current Report |
| Feb 6, 2026 | SCHEDULE 13G | Filing |
| Feb 6, 2026 | 8-K | Current Report |
| Feb 3, 2026 | SCHEDULE 13G | Filing |
| Feb 2, 2026 | SCHEDULE 13G | Filing |
| Feb 2, 2026 | 8-K | Current Report |
| Jan 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |